ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Barclays PLC

Barclays PLC raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 9.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 157,060 shares of the specialty pharmaceutical company's stock after purchasing an additional 14,027 shares during the quarter. Barclays PLC owned about 0.75% of ANI Pharmaceuticals worth $8,682,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after purchasing an additional 340,854 shares during the period. abrdn plc acquired a new stake in ANI Pharmaceuticals during the 4th quarter worth about $13,155,000. Assenagon Asset Management S.A. boosted its position in shares of ANI Pharmaceuticals by 67.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company's stock worth $17,226,000 after buying an additional 125,438 shares during the period. Global Alpha Capital Management Ltd. grew its position in ANI Pharmaceuticals by 16.4% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock valued at $34,525,000 after purchasing an additional 88,100 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at about $3,916,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ANIP has been the topic of a number of research analyst reports. Guggenheim reaffirmed a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a report on Friday, April 11th. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price on the stock. StockNews.com cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 target price for the company. Finally, Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a report on Monday, April 21st. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock traded up $0.61 during trading hours on Tuesday, hitting $71.36. 32,084 shares of the company were exchanged, compared to its average volume of 276,082. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -129.67 and a beta of 0.49. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The firm has a fifty day simple moving average of $64.46 and a 200 day simple moving average of $59.99. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $72.29.

Insider Buying and Selling

In other news, VP Meredith Cook sold 400 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares of the company's stock, valued at $5,100,914.85. This represents a 0.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the sale, the senior vice president now directly owns 68,624 shares of the company's stock, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,200 shares of company stock worth $197,792. Corporate insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.